AXIM Biotechnologies has developed the next-generation version of its Covid-19 Rapid Neutralizing Antibody Test.
The company’s first rapid test is currently under review by the US Food and Drug Administration (FDA).
Antiviral antibodies are easy to detect and measure using a drop of blood.
If levels of neutralising antibodies in the blood are high enough, they protect individuals from Covid-19 infection.
Covid-19 vaccines are developed to induce antibodies against SARS-CoV-2 virus to prevent infection. However, not all antibodies neutralise the virus and provide protection from the disease.
